Skip to main content

Table 2 ORRs (RECIST) in patients positive for RET biomarkers

From: A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Clinical study

Objective responses, n/N (%)

RETrearrangement

RETamplification

LowRETgene copy number gain

RET expression

Van

Comp

Van

Comp

Van

Comp

Van

Comp

ZODIAC + ZEAL

0/1

1/2

1/6

1/7

2/14

2/14

5/16

3/24

ZEPHYR

0/2

0/1

0/2

0/3

0/19

0/5

0/18

0/10

ZEST

0/0

0/1

0/4

0/2

2/8

1/14

2/12

3/10

Overall

0/3 (0.0)

1/4 (25.0)

1/12 (8.3)

1/12 (8.3)

4/41 (9.8)

3/33 (9.1)

7/46 (15.2)

6/44 (13.6)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us